✨ Free AI Report
Tonix Pharmaceuticals Holding Corp.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Tonix Pharmaceuticals Holding Corp.
Company Research

Tonix Pharmaceuticals Holding Corp.: Business Overview, Financials & Competitive Analysis

Tonix Pharmaceuticals Holding Corp. scores 6/10 on the AskCyborg Cyborg Score (Solid). Early-stage commercial biotech with FDA-approved fibromyalgia treatment and promising pipeline, but elevated risk profile dependent on clinical trial success and market adoption. In 2024, TNXP's revenue was $10.09 million, an increase of 29.94% compared to the previous year. The company has achieved commercial milestone with Tonmya launch but.

What is Tonix Pharmaceuticals Holding Corp.'s industry? Tonix Pharmaceuticals Holding Corp. (tonixpharma.com) operates in Biopharmaceutical - CNS Disorders, Pain Management, Immunology, Infectious Disease, and Rare Disease. AskCyborg classifies Tonix Pharmaceuticals Holding Corp. under Biopharmaceutical - CNS Disorders, Pain Management, Immunology, Infectious Disease, and Rare Disease in its company registry.

Tonix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and prevent human disease. The company received FDA approval and launched Tonmya, the first new fibr...

6/ 10Solid

Cyborg Score thesis

Early-stage commercial biotech with FDA-approved fibromyalgia treatment and promising pipeline, but elevated risk profile...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - CNS Disorders, Pain Management, Immunology, Infectious Disease, and Rare Disease
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Tonix Pharmaceuticals Holding Corp. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Tonix Pharmaceuticals Holding Corp.

AskCyborg analysts argue the bull and bear cases for Tonix Pharmaceuticals Holding Corp. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Tonix Pharmaceuticals Holding Corp. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Tonix Pharmaceuticals Holding Corp. Overview

Pro stress-test →

Tonix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and prevent human disease. The company received FDA approval and launched Tonmya, the first new fibromyalgia drug in over 15 years, and markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Strategic Profile

Pro stress-test →

The company's portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. Tonix has made significant strides with a $20 million registered direct offering and updates on its promising drug candidates, including TNX-4800 for Lyme disease prevention and TNX-4900 for chronic pain.

Competitive Landscape

Pro stress-test →

Tonix markets migraine treatments Zembrace SymTouch and Tosymra. The company competes in multiple therapeutic areas including CNS disorders, pain management, immunology, and rare diseases, with differentiation through its newly approved Tonmya fibromyalgia treatment and innovative pipeline programs targeting underserved indications like Lyme disease prevention.

Industry Context

Tonix Pharmaceuticals Holding Corp. operates in Biopharmaceutical - CNS Disorders, Pain Management, Immunology, Infectious Disease, and Rare Disease.

Key facts

Founded: 2011 · Headquarters: Berkeley Heights, NJ, US · Revenue: $10.09M (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Tonix Pharmaceuticals Holding Corp..

  • Tonmya is the first FDA-approved fibromyalgia treatment in over 15 years, representing a significant commercial opportunity in an underserved market.
  • TNX-4800, targeting seasonal Lyme disease prevention, plans an FDA meeting in 2026 to explore Phase 2/3 options with potential applicability to ~70 million people in U.S. Lyme-endemic areas.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Scheduled to participate in two investor conferences in March
  • January 2026Presented Phase 3 RESILIENT data on TONMYA showing statistically significant pain reduction at Week 14
  • +1 moreTrack every material event for Tonix Pharmaceuticals Holding Corp. as it happens. Explore monitoring →
Get alerted when Tonix Pharmaceuticals Holding Corp. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Fibromyalgia treatmentsEstablished pain management franchise→Migraine therapeuticsCompeting migraine prevention and acute treatments→CNS disorder therapiesOther CNS-focused biotech companies→

Compare Tonix Pharmaceuticals Holding Corp. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Tonix Pharmaceuticals Holding Corp. operates in Biopharmaceutical - CNS Disorders, Pain Management, Immunology, Infectious Disease, and Rare Disease. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - CNS Disorders, Pain Management, Immunology, Infectious Disease, and Rare Disease research →
NEW · MCP server

Ask your AI assistant about Tonix Pharmaceuticals Holding Corp.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Tonix Pharmaceuticals Holding Corp. and its top competitor on Cyborg Score”
“What did Tonix Pharmaceuticals Holding Corp. do this quarter?”
“Is Tonix Pharmaceuticals Holding Corp. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Tonix Pharmaceuticals Holding Corp. do?+
Tonix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and prevent human disease. The company received FDA approval and launched Tonmya, the first new fibr...
What is Tonix Pharmaceuticals Holding Corp.'s Cyborg Score?+
Tonix Pharmaceuticals Holding Corp. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Tonix Pharmaceuticals Holding Corp.'s main competitors?+
Named competitors include Fibromyalgia treatments, Migraine therapeutics, CNS disorder therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Tonix Pharmaceuticals Holding Corp. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Tonix Pharmaceuticals Holding Corp. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Tonix Pharmaceuticals Holding Corp. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.